Harvey Capital Management Inc. reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 92,345 shares of the biopharmaceutical company’s stock after selling 2,750 shares during the quarter. Gilead Sciences makes up 3.1% of Harvey Capital Management Inc.’s investment portfolio, making the stock its 7th largest position. Harvey Capital Management Inc.’s holdings in Gilead Sciences were worth $5,776,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of the business. Crossmark Global Holdings Inc. boosted its position in shares of Gilead Sciences by 4.3% in the fourth quarter. Crossmark Global Holdings Inc. now owns 212,409 shares of the biopharmaceutical company’s stock worth $13,286,000 after acquiring an additional 8,833 shares during the last quarter. Wedge Capital Management L L P NC boosted its position in shares of Gilead Sciences by 4.4% in the fourth quarter. Wedge Capital Management L L P NC now owns 495,444 shares of the biopharmaceutical company’s stock worth $30,990,000 after acquiring an additional 20,887 shares during the last quarter. Intercontinental Wealth Advisors LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter worth approximately $80,000. Advisors Asset Management Inc. boosted its position in shares of Gilead Sciences by 45.5% in the fourth quarter. Advisors Asset Management Inc. now owns 91,175 shares of the biopharmaceutical company’s stock worth $5,703,000 after acquiring an additional 28,507 shares during the last quarter. Finally, Handelsbanken Fonder AB boosted its position in shares of Gilead Sciences by 1.0% in the fourth quarter. Handelsbanken Fonder AB now owns 326,870 shares of the biopharmaceutical company’s stock worth $20,446,000 after acquiring an additional 3,300 shares during the last quarter. Hedge funds and other institutional investors own 80.03% of the company’s stock.
Shares of Gilead Sciences stock opened at $67.47 on Monday. The company has a current ratio of 3.36, a quick ratio of 3.29 and a debt-to-equity ratio of 1.09. The stock has a market capitalization of $87.28 billion, a price-to-earnings ratio of 10.97, a price-to-earnings-growth ratio of 66.65 and a beta of 1.19. Gilead Sciences, Inc. has a 52 week low of $60.32 and a 52 week high of $82.71.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 28th. Shareholders of record on Friday, March 15th will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.73%. The ex-dividend date is Thursday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.57. Gilead Sciences’s payout ratio is presently 37.07%.
Several equities research analysts recently issued reports on GILD shares. BidaskClub raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, November 8th. Raymond James reissued a “buy” rating on shares of Gilead Sciences in a research report on Thursday, November 1st. Mizuho set a $94.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Thursday, November 1st. Evercore ISI reissued a “buy” rating on shares of Gilead Sciences in a research report on Wednesday, October 31st. Finally, Guggenheim assumed coverage on shares of Gilead Sciences in a research report on Monday, December 17th. They set a “buy” rating and a $86.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and a consensus target price of $86.85.
In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the business’s stock in a transaction dated Monday, December 3rd. The stock was sold at an average price of $71.20, for a total transaction of $3,560,000.00. Following the sale, the director now owns 2,877,762 shares in the company, valued at approximately $204,896,654.40. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.16% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Holdings Trimmed by Harvey Capital Management Inc.” was published by WKRB News and is the property of of WKRB News. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.wkrb13.com/2019/02/11/gilead-sciences-inc-gild-holdings-trimmed-by-harvey-capital-management-inc.html.
Gilead Sciences Profile
Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Read More: Capital Gains
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.